Analysis of clinical indicators based on Ann Arbor staging revealed that CHI3L1 levels were significantly higher in stage III-IV patients than in stage I-II patients (P = 0.001), suggesting that this biomarker is associated with tumor progression. The gene discussed is CHI3L1; the disease is neoplasm.